Loading company
Monopar Therapeutics
MNPR · Nasdaq · ·
$80.02-4.5%Sep 29 close
- 1M
- -28.5%
- 6M
- +50.2%
- 1Y
- -2.0%
- 5Y
- +218.2%
MNPR · Nasdaq · ·
$80.02-4.5%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$5.3M | -$2.5M | -116.56% |
| Profit per share | -$0.19 | -$0.16 | -18.75% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Monopar Therapeutics has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body’s ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Monopar Therapeutics’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.